A new cancer drug from Cambridge-based Ariad Pharmaceuticals has helped nearly half of chronic myeloid leukemia patients in a 12-month trial achieve a "complete cytogenetic response" — meaning their bone marrow is cancer-free.
Company shares, which closed at $22.07 on Friday, rose more than 5 percent this morning to a high of $23.20.
Data from the trial of ponatinib was presented yesterday at the 54th Annual Meeting of the American Society of Hematology in Atlanta.
Ariad said it filed for regulatory approval of ponatinib this year in the United States and Europe based on clinical data from the trial.
The trial of ponatinib involved 444 patients, including 267 with chronic myeloid leukemia, who had previously been treated with other drugs. A total of 46 percent of patients in the trial achieved a complete cytogenetic response, while 56 percent achieved a "major cytogenetic response," meaning their bone marrow is nearly cancer-free.
Anda sedang membaca artikel tentang
Ariad rises on positive leukemia drug results
Dengan url
http://kapalnelayanto.blogspot.com/2012/12/ariad-rises-on-positive-leukemia-drug.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Ariad rises on positive leukemia drug results
namun jangan lupa untuk meletakkan link
Ariad rises on positive leukemia drug results
sebagai sumbernya
0 komentar:
Posting Komentar